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Abstract 18 
Chagas’ disease, which is caused by the Trypanosoma cruzi parasite, has become a global health 19 
problem that is currently treated with poorly tolerated drugs that require prolonged dosing. Therefore, 20 
there is a clinical need for new therapeutic agents that can mitigate these issues. The 21 
phosphomannomutase (PMM) and guanosine diphosphate-mannose pyrophosphorylase (GDP-MP) 22 
enzymes form part of the de novo biosynthetic pathway to the nucleotide sugar guanosine 23 
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diphosphate-mannose. This nucleotide sugar is used either directly, or indirectly via the formation of 24 
dolichol-phosphomannose, for the assembly of all mannose-containing glycoconjugates. In T. cruzi, 25 
mannose-containing glycoconjugates include the cell-surface glycoinositol-phospholipids and the 26 
glycosylphosphatidylinositol-anchored mucin-like glycoproteins that dominate the cell surface 27 
architectures of all life-cycle stages. This makes PMM and GDP-MP potentially attractive targets for 28 
a drug discovery programme against Chagas’ disease. To assess the ligandability of these enzymes in 29 
T. cruzi, we have screened 18,117 structurally diverse compounds exploring drug-like chemical space 30 
and 16,845 small polar fragment compounds using an assay interrogating activities of both PMM and 31 
GDP-MP enzymes simultaneously. This resulted in 48 small fragment hits, and on re-testing 20 were 32 
found to be active against the enzymes. Deconvolution revealed that these were all inhibitors of T. 33 
cruzi GDP-MP, with compounds 2 and 3 acting as uncompetitive and competitive inhibitors, 34 
respectively. Based on these findings, the T. cruzi PMM and GDP-MP enzymes were deemed not 35 
ligandable and poorly ligandable, respectively, using small-molecules from conventional drug 36 
discovery chemical space. This presents a significant hurdle to exploiting these enzymes as 37 
therapeutic targets for Chagas’ disease.  38 
      39 
Introduction 40 
Chagas’ disease is a vector borne disease, caused by the parasite Trypanosoma cruzi, with an 41 
increasing global health burden due to migration between endemic Latin American and non-endemic 42 
countries. This is signified by the estimated 7-8 million people that are infected with T. cruzi 43 
worldwide, of which 300,000 are estimated to live in the United States and 59,000–108,000 in Europe 44 
(1). Infection with T. cruzi is first associated with an acute phase that tends to last up to approximately 45 
8 weeks and, in most cases, patients present with non-specific symptoms such inflammation at the site 46 
of parasite entry and fever. The acute phase usually resolves spontaneously and most patients will 47 
enter an indeterminate chronic phase, where infection with T. cruzi persists in the absence of clinical 48 
symptoms and with good prognosis. However, approximately 30–40% of chronically infected patients 49 
will develop cardiac or gastrointestinal organ involvement over time, which can be fatal (2). For the 50 
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last four decades, treatment of Chagas’ disease has been limited to benznidazole and nifurtimox, both 51 
of which are nitroheterocyclic drugs (3). Unfortunately, therapeutic failures are commonplace due to 52 
the long duration of treatments required with these drugs and their broad side effect profiles (2–3), 53 
although the recent BENDITA clinical trial offers promise of a more effective and shorter term 54 
treatment regimen (4). Despite this, there is a clear clinical need for new treatments against Chagas’ 55 
disease that are better tolerated and require shorter dosage regimens. One way to achieve this is 56 
through a focused drug-discovery programme targeting a validated biochemical pathway that is 57 
essential for parasite viability and/or virulence. 58 
 59 
T. cruzi is known to produce an array of mannose-containing glycoconjugates, such as glycoinositol 60 
phospholipids (GIPLs) and glycosylphosphatidylinositol (GPI) anchored mucin-like glycoproteins, 61 
trans-sialidase enzymes, and other N-glycosylated glycoproteins, which coat the outer surface of the 62 
parasite (5–8). Amongst other things, these glycoconjugates play an important role in parasite 63 
virulence, and their ability to enter host cells (5–8).  Importantly, genetic disruption of the biosynthetic 64 
pathway responsible for the production of similar glycoconjugate structures in related trypanosomatid 65 
parasites has been shown to be lethal to T. brucei (9–12) and to render Leishmania mexicana (13–16) 66 
and L. major (17) either less virulent or completely avirulent. A key intermediate in the production of 67 
these glycoconjugate structures is guanosine diphosphate-mannose (GDP-Man), which acts as a donor 68 
of activated mannose for glycosylation reactions. GDP-Man is known to be present at low basal levels 69 
in T. cruzi, T. brucei, and L. major, and this has been linked to the high flux of this substrate in 70 
trypanosomatids (6). This, coupled with the above-mentioned genetic findings, highlights the 71 
biological importance of GDP-Man in these parasites.  72 
 73 
In eukaryotes, GDP-Man is generated through a series of successive enzymatic reactions, where the 74 
penultimate step involves the conversion of mannose-6-phosphate (M-6-P) to mannose-1-phosphate 75 
(M-1-P) by the phosphomannomutase (PMM) enzyme through a transfer of a phosphate functionality, 76 
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made available by the glucose-1,6-bisphosphate (G-1,6-BP) co-factor, from the C-6 position to the C-77 
1 position of the mannose sugar (6, 17). It is important to note that this transformation is not 78 
associated with a mass change and cannot be measured directly using standard biochemical 79 
approaches in a high-throughput manner. The next step in this pathway involves the addition of M-1-80 
P into the guanosine-monophosphate moiety of guanosine triphosphate (GTP) by the guanosine 81 
diphosphate-mannose pyrophosphorylase (GDP-MP) enzyme to produce GDP-Man (6, 18) (Figure 1). 82 
Drug discovery efforts utilising high-throughput screening (19) and target-based design (20) 83 
approaches have been able to identify a small number of inhibitors of the L. mexicana and L. 84 
donavani GDP-MP enzymes that were capable of killing the parasites in vitro.  85 
 86 
Collectively, the above findings provide genetic and pharmacological evidence for the GDP-Man 87 
biosynthetic pathway as a target for new drugs against Leishmania and T. brucei parasites. However, 88 
the ability of T. cruzi PMM and GDP-MP to bind small molecules other than substrates in vitro, 89 
defined as ligandability (21), remains an open question. In order to address this knowledge gap, we 90 
have developed a high-throughput, colourimetric PMM and GDP-MP enzyme assay system to 91 
measure the collective output of both enzymes and a GDP-MP assay that measures the output of the 92 
single enzyme as a hit de-convolution strategy. Moreover, both assay platforms were further expanded 93 
to allow for interrogation of enzyme activities at different substrate concentrations (i.e. standard and 94 
high-substrate configurations) (Figure 2). These tools were used to screen a subset of our diverse 95 
compound libraries and a focused small polar fragment library in an effort to identify chemical matter 96 
capable of inhibiting T. cruzi PMM and/or GDP-MP, and subsequently further profile the 97 
pharmacology of hits of interest. Ultimately, the findings from these studies were used to assess the 98 
ligandability of the target T. cruzi PMM and GDP-MP enzymes.  99 
 100 
 101 
 102 
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 103 
Results 104 
Biochemical assay development. 105 
To identify suitable screening substrate concentrations, Michaels-Menten constants (Km) were 106 
acquired for M-1-P and GTP substrates using the GDP-MP assay, followed by M-6-P and G-1,6-BP 107 
using the PMM-GDP-MP assay (Figure 3 and Table 1). Multiple configurations of the assays were set 108 
up for screening and/or further pharmacological assessment using final substrate concentrations either 109 
approximately equivalent to Km values (standard configuration) or 5 to 10-fold Km values (high-110 
substrate configurations). Linearity of both the GDP-MP and PMM-GDP-MP assays was investigated 111 
using the standard and high-substrate configurations. In the case of the GDP-MP assay, a linear 112 
response for up to 50 min (R2 = 0.98 and 0.99 respectively) was observed using both standard and 113 
high-substrate configurations (Figure S1a). The PMM-GDP-MP assay biochemical response was 114 
associated with an initial lag phase of 30 min for both assay configurations, followed by a subsequent 115 
linear response for the remaining 60 min of the standard configuration time course reaction (R2 = 116 
0.99). The lag-phase was likely due to the need to build up M-1-P substrate by the PMM enzyme for 117 
the successive GDP-MP biochemical reaction. Time-course assay linearity was slightly shorter for the 118 
high-substrate assay configuration (i.e. 30–80 min; R2 = 0.99). Finally, as our screening compound 119 
libraries are formulated in dimethyl sulfoxide (DMSO), the tolerance of the biochemical assays to this 120 
solvent were investigated. Both the GDP-MP and PMM-GDP-MP biochemical assays were shown to 121 
be tolerant to DMSO up to 2% v/v (Figure S2).   122 
 123 
The biochemical assays rely on the detection of pyrophosphate using a colourimetric reporter system 124 
comprising of a pyrophosphatase enzyme that generates free inorganic phosphate, which in turn reacts 125 
with the BIOMOL® Green reagent to generate a quantitative colourimetric response. To identify 126 
compounds capable of interfering with the pyrophosphatase and BIOMOL® Green reporter, a counter-127 
screen assay was established looking at this system in isolation. A titration of sodium pyrophosphate 128 
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in the presence of a fixed concentration of pyrophosphatase reporter enzyme, which matched that used 129 
for the GDP-MP and PMM-GDP-MP biochemical assays, revealed complete turnover of 130 
pyrophosphate in less than one minute (Figure S3a). Importantly, the measured response signal was 131 
linear (R2 = 0.99) relative to pyrophosphate concentration (Figure S3b). 132 
 133 
Diversity screening and hit confirmation. 134 
Single point screening of a diverse set of 18,117 compounds using the standard configuration PMM-135 
GDP-MP assay platform failed to identify any chemical matter capable of inhibiting the biochemical 136 
activity of these enzymes by 30% or more at a compound concentration of 10 µM (Figure 4a). 137 
However, screening a compound library comprising 16,845 small polar fragments at a higher 138 
compound concentration of 300 µM identified 48 hits at ≥30% inhibition (0.29% hit-rate) (Figure 4b).  139 
Mean robust Z’ values of 0.87 ± 0.04 (SD; N = 60) and 0.90 ± 0.03 (SD; N = 52) were obtained for 140 
the former and latter screens, where a Z’ of >0.5 signifies a highly robust biochemical assay (22).    141 
 142 
In order to establish the potency and confirm the presence or absence of technology interference, hit 143 
compounds that were available (46 out of the 48) underwent concentration-response assessment using 144 
the standard configuration PMM-GDP-MP and reporter counter-screen biochemical assays. Excellent 145 
linear correlations were established between the calculated pIC50 parameters, defined as –log(IC50 146 
(M)), for independent assay replicates (Figures 5a and 5b). Out of the tested initial hit compounds, 147 
inhibitory activity (i.e. mean pIC50 ≥3 (N = 2)) against the GDP-MP and/or PMM enzymes was 148 
established for 20 compounds, while the remaining compounds were either inactive (i.e. 13 149 
compounds with mean pIC50 <3 (N = 2)) or were deemed to be technology interferers (i.e. 13 150 
compounds with mean pIC50 ≥3 (N = 2) in the counter-screen) (Figure 5c). To deconvolute the 151 
enzymatic target of the 20 hits, concentration-response assessment was also performed using the 152 
standard configuration GDP-MP enzymatic assay (Figure 6). Out of the 20 hits, compound 1 153 
exhibited much greater potency in both the PMM-GDP-MP and GDP-MP assays compared to the 154 
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remaining compounds (Figure 6 and Table 2). However, this compound has been identified as a hit 155 
against a number of other enzymes in our previous screening efforts and was deemed to be a 156 
promiscuous inhibitor. Compound 2 appeared to be active in the standard configuration PMM-GDP-157 
MP assay but inactive in the standard configuration GDP-MP assay (Figure 6 and Table 2), 158 
suggesting inhibitory activity against the PMM enzyme. To confirm the activity of compounds 2 and 159 
3, fresh solid material was obtained and both demonstrated activity in the standard and high-substrate 160 
configurations of the PMM-GDP-MP assay (Table 2, and Figure S4a and S4c). In line with the poor 161 
level of enzyme inhibition, compounds 1–4 were inactive in our intracellular T. cruzi phenotypic 162 
assay (23) at 100 µM. Interestingly, 2 was shown to be inactive against the GDP-MP enzyme when 163 
tested using the standard configuration assay, but capable of inhibition when substrate concentrations 164 
were increased by 10-fold (i.e. using the high-substrate configuration assay) (Table 2 and Figure S4b), 165 
indicative of uncompetitive inhibition. The re-purchased stock of compound 3 was also confirmed to 166 
be active in the standard configuration GDP-MP assay (Table 2 and Figure S4d), with an observable 167 
shift in the concentration response curve and a subsequent drop in the pIC50 parameter when the high-168 
substrate configuration of the assay was used, indicative of competitive inhibition.       169 
 170 
Discussion. 171 
With the appropriate biochemical tools in place, we sought to address the knowledge gap of T. cruzi 172 
PMM and GDP-MP enzyme ligandability. Our initial efforts to identify inhibitors of either the T. 173 
cruzi PMM or the GDP-MP enzymes by performing a screen of 18,117 compounds exploring a 174 
diverse range of chemical space using the standard configuration PMM-GDP-MP assay platform were 175 
not successful (Figure 4a). On the whole, the active sites of the PMM and GDP-MP enzymes exhibit a 176 
high level of homology between species (17, 20, 24) and Leishmania GDP-MP enzymes have been 177 
found to be ligandable by drug-like compounds. Lackovic et al reported an initial hit rate of 178 
approximately 0.6% following a screen of approximately 80,000 compounds against L. major GDP-179 
MP. Following confirmation and technology interference counter-screening and hit expansion, the 180 
authors identified 21 inhibitors with cell-free pIC50 values spanning a range of 5.0 to 6.3. The majority 181 
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of these compounds were classified into three distinct chemotypes, namely pyrazolin-3,5-diones, 4-182 
pyrizinylquinolines, and thiadiazole-like compounds (19). In addition to this, Mao et al detailed 4 183 
further inhibitors with pKi values ranging from 4.6 to 5.2 against L. mexicana and L. donovani GDP-184 
MP enzymes (20).  None of the previously published compounds were part of the screening sets used 185 
here. The screens did include a number of compounds with 4-pyrizinylquinoline and thiadiazole-like 186 
cores, which were all inactive in the standard configuration PMM-GDP-MP assay. As no Leishmania 187 
enzyme data is available for these specific compounds, this information does not provide insight into 188 
the differences in ligandability between the Leishmania and T. cruzi enzymes.  189 
 190 
It is possible that the apparent lower level of ligandability of T. cruzi PMM and/or GDP-MP 191 
compared to the Leishmania enzymes is due to subtle structural differences between the parasite 192 
species, which may drive the observed marked differences in the kinetic properties of the different 193 
GDP-MP enzymes. Mao et al observed that the catalytic efficiency of the L. mexicana GDP-MP 194 
enzyme for M-1-P and GTP substrates was 10- and 20-fold higher, respectively, than the equivalent L. 195 
donovani enzyme (20).  Moreover, our GTP Km value for T. cruzi GDP-MP was 2.4-, 5.3- and 27-fold 196 
higher than reported for L. donavani, L. mexiciana and L. major respectively, while the T. cruzi M-1-197 
P Km parameter value was in line with the reported Leishmania Km values (19–20).
  198 
 199 
By taking into account the polar nature of the substrates and/or co-factors for the PMM and GDP-MP 200 
enzymes, we attempted to bias our hunt for inhibitors of these T. cruzi enzymes by performing a 201 
screen using a focused compound library comprising of 16,845 small polar molecules. The use of 202 
lower molecular weight compounds for screening campaigns is usually associated with the 203 
identification of hits exhibiting weak inhibitory properties, which is an inherent consequence of the 204 
reduced number of potential interactions that can take place between a small fragment and the target 205 
enzyme (25). With this in mind, compounds from the small polar library were tested at a higher 206 
concentration of 300 µM compared to the previously screened compound sets. This endeavour was 207 
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more successful as a small number of hits capable of inhibiting the biochemical response of the T. 208 
cruzi PMM-GDP-MP assay were identified. An initial de-convolution screen using the standard 209 
configuration GDP-MP assay showed that the majority of the compounds were also active in this 210 
assay, indicating that these were inhibitors of GDP-MP. The exception to this was compound 2 that 211 
showed marked activity against the standard configuration PMM-GDP-MP assay, but appeared 212 
inactive in the standard configuration GDP-MP deconvolution assay, suggesting that 2 was an 213 
inhibitor of the T. cruzi PMM enzyme. However, on further concentration-response evaluation, 214 
compound 2 was found to display behaviour that is consistent with uncompetitive GDP-MP enzyme 215 
inhibition, where the GTP substrate molecule must first be bound to the enzyme to allow binding of 216 
the inhibitory compound (26). This is supported by the similar pIC50 values obtained for 2 using the 217 
standard configuration PMM-GDP-MP and high-substrate configuration GDP-MP assays that both 218 
utilised the GTP substrate at saturating concentrations, and the lack of activity in the standard 219 
configuration GDP-MP assay where the GTP substrate was used at a concentration approximating its 220 
Km value. In contrast to this, compound 3 exhibited behaviour that was suggestive of competitive 221 
inhibition of the T. cruzi GDP-MP enzyme, as exemplified by the observable shift in the dose 222 
response curve and the corresponding decrease in the pIC50 value following a 10-fold increase in 223 
biochemical assay substrate concentrations.  224 
 225 
In summary, our inability to identify and confirm a single inhibitor of the T. cruzi PMM enzyme from 226 
a total of 34,962 compounds exploring both drug-like and small polar compounds suggests that, in 227 
this particular chemical space, T. cruzi PMM is not ligandable. Moreover, based on criteria reported 228 
by Edfeldt et al (21), the T. cruzi GDP-MP was deemed to be poorly ligandable as only a small 229 
number of polar fragment-like hits were identified, which exhibited weak inhibitory properties in our 230 
cell free biochemical assays. Therefore, despite genetic and pharmacological evidence for PMM and 231 
GDP-MP enzymes as potential therapeutic targets for leishmaniasis, the apparent poor ligandability of 232 
the T. cruzi variants presents an important hurdle for exploiting these targets for Chagas’ disease drug 233 
discovery. 234 
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 235 
 236 
 237 
 238 
Materials and Methods. 239 
General. 240 
All enzyme and substrate solution dilutions were prepared in assay buffer comprising 25 mM Tris-241 
HCl (pH 7.5), 150 mM NaCl, 4 mM MgCl2, 0.01% v/v Tween 20, and 1 mM dithiothreitol in 242 
ultrapure water. Biochemical assays were performed in a 50 µL final assay volume using clear 384-243 
well assay microplates (Greiner; catalogue no. 781101) at room temperature. Unless stated otherwise, 244 
all reagent concentrations are written as final biochemical assay concentrations, and DMSO or 245 
compounds were added to assay plates using Echo acoustic dispensers (Labcyte, USA). Reagent 246 
addition for high-throughput screening assays was performed using an Xrd-384 liquid dispenser 247 
(FluidX, UK) and a BioFill Solo/Xrd-384 16 channel resin nozzle (2.00–200 µL) tubing cartridge 248 
(FluidX; catalogue no. 34-1005-S). Biochemical reactions were terminated by addition of 50 µL of 249 
BIOMOL® Green (Enzo Life Sciences; catalogue no. BML-AK111-1000) reagent, after which 250 
absorbance was measured following a 30 minute incubation at room temperature. Absorbance 251 
measurements were performed at 650 nm using a PHERAStar microplate reader (BMG Labtech, 252 
Germany) and the data are represented as relative absorbance units (RAU). Linear and non-linear 253 
regression was performed using the SigmaPlot 12.5 software, unless stated otherwise. 254 
 255 
T. cruzi PMM and GDP-MP production and purification. 256 
The genes coding for T. cruzi GDP-MP and PMM (UniProtKB Q4CMK4 and Q4E4A3, respectively) 257 
were synthesised, followed by optimisation of the codons for E. coli by GenScript and cloning into 258 
modified pET15b with an N-terminal histidine and maltose-binding protein tag and TEV cleavage site 259 
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for GDP-MP, and an N-terminal histidine tag and TEV cleavage site for PMM. The respective 260 
plasmids were transformed into BL21 DE3 E. coli cells, and autoinduction media (1 L for GDP-MP 261 
and 2 L for PMM) supplemented with AMP was inoculated and grown for 4 hours at 37 °C, followed 262 
by a further 17 hours at 20 °C. Cell pellets were generated by centrifugation at 3,500 g for 20 min, 263 
and in each case the supernatant was discarded. The pellets were resuspended in 20 mL of lysis buffer 264 
(i.e. 25 mM Tris, pH 8.5; 500 mM NaCl; 20 mM imidazole; 1 cOmpleteTM Protease Inhibitor Cocktail 265 
tablet (Roche, Germany)) and the resulting suspension was then passed through a continuous flow cell 266 
disruptor (Constant Systems Ltd., UK) at 30 KPSI. The T. cruzi GDP-MP sample was then 267 
centrifuged at 37,500 g for 30 min and filtered (0.45 µm), and the PMM sample was centrifuged at 268 
40,000 g for 30 min  and filtered (0.22 µm). 269 
   270 
To purify the proteins, a 5 mL HisTrapTM Ni HP column (GE Healthcare, USA) was first equilibrated 271 
with buffer ‘A’ (i.e. 25 mM Tris, pH 8.5; 500 mM NaCl; 20 mM imidazole) using an ÄKTATM pure 272 
chromatography system (GE Healthcare, USA) followed by loading of protein sample at 5 mL/min. 273 
Next the column was washed with 10 column volumes of buffer ‘A’, followed by 10 column volumes 274 
of 5% v/v buffer ‘B’ (i.e. 25 mM Tris, pH 8.5; 500 mM NaCl; 0.5 mM TCEP; 500 mM imidazole) to 275 
remove histidine-rich contaminating proteins. A gradient of 5% v/v to 50% v/v buffer ‘B’ was then 276 
used to elute the proteins. TEV protease was added to the protein samples (7 mg for GDP-MP and 2 277 
mg for PMM), which were then dialysed against buffer ‘C’ (i.e. 25 mM Tris, pH 7.5; and 250 mM 278 
NaCl). The proteins were passed through the 5 mL HisTrapTM Ni HP column (GE Healthcare, USA) 279 
to remove the TEV protease and any uncleaved proteins, where cleaved proteins were retained on the 280 
column. A gradient of 0% v/v to 50% v/v of buffer ‘B’ over 10 column volumes was applied to 281 
remove the cleaved protein from the histidine and/or maltose binding protein, and TEV. Protein 282 
samples were concentrated to 11 mL using 30 kDa cut-off VivaspinTM protein concentrators 283 
(Sartorius, Germany), filtered (0.22 µm), and loaded onto XK26/60 Superdex 200 and 75 columns 284 
(GE Healthcare, USA), for GDP-MP and PMM respectively, which were previously equilibrated with 285 
buffer ‘C’. Protein loading was performed using a 10 mL loop at 1 mL/min. The GDP-MP and PMM 286 
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proteins were eluted using buffer ‘C’ as hexamers and dimers respectively (columns were calibrated 287 
with Bio-Rad (USA) standards). T. cruzi GDP-MP was concentrated to 2.49 mg/mL and a total yield 288 
of 12 mg was achieved. T. cruzi PMM was concentrated to 5.77 mg/mL and a total yield of 3.24 mg 289 
was achieved. Mass-spectrometry was used to confirm the identity of the proteins and densitometry 290 
(measured using a Bio-Rad imager (Bio-Rad, USA)) was used to confirm that both protein samples 291 
exhibited 100% purity.                292 
Primary assay development. 293 
To calculate the Michaelis constant (Km) for the M-1-P substrate, 20 minute time-course reactions 294 
using a fixed concentration of GDP-MP enzyme (3.13 nM), a saturating concentration of GTP 295 
substrate (600 µM) mixed with inorganic pyrophosphatase (1 U/mL; Merck, catalogue no. I5907-296 
1MG), and varying concentrations of M-1-P substrate (150 µM; 75 µM; 37.5 µM; 18.8 µM; 9.38 µM; 297 
4.69 µM; and 2.34 µM) were performed. The Km for the GTP substrate was acquired in a similar 298 
manner using a saturating concentration of M-1-P (150 µM) and varying concentrations of GTP 299 
substrate (300 µM; 150 µM; 75 µM; 37.5 µM; 18.8 µM; 9.38 µM; and 4.69 µM). In both cases, 300 
background control samples were also included that lacked the presence of GDP-MP enzyme. At the 301 
end of the time courses, the biochemical reactions were terminated and absorbance measurements 302 
were taken. Background signal was subtracted and linear regression was performed on the 303 
corresponding time versus activity plots in order to acquire relative reaction rates, which were in turn 304 
used to generate classical Michaelis-Menten plots. Data were acquired from 3 independent replicates 305 
(N = 3) and are represented in the figures as mean values ± SD.  The Km was obtained by fitting 306 
individual replicate data to the Michaelis-Menten equation shown below: 307 
𝑣 =
𝑉𝑚𝑎𝑥[S]
𝐾m + [S]
 
 308 
To measure the activity of the T. cruzi PMM enzyme, a PMM-GDP-MP biochemical assay system 309 
was used. Km determinations for the M-6-P substrate and G-1,6-BP co-factor were acquired as 310 
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described above by performing 60 minute time-course reactions. Fixed concentrations of PMM and 311 
GDP-MP enzyme (6.25 nM and 3.13 nM, respectively), a saturating concentration of GTP (300 µM) 312 
mixed with inorganic pyrophosphatase (1 U/mL), and either a saturating concentration of M-6-P (300 313 
µM) or G-1,6-BP (60 µM) and varying concentrations of either G-1,6-BP (i.e. 50 µM; 25 µM; 12.5 314 
µM; 6.25 µM; 3.13 µM; 1.57 µM; and 0.78 µM) or M-6-P (i.e. 800 µM; 400 µM; 200 µM; 100 µM; 315 
50 µM; 25 µM; and 12.5 µM) were used. Data were acquired from 3 independent replicates (N = 3) 316 
and are represented in the figures as mean values ± SD. 317 
 318 
To confirm linearity of the GDP-MP assay in the standard and high-substrate configurations, a 50 319 
minute time-course reaction was performed using either 3.13 nM or 0.78 nM of GDP-MP enzyme, 320 
respectively, in the presence of M-1-P (15 µM or 150 µM), GTP (30 µM or 300 µM), and inorganic 321 
pyrophosphatase (1 U/mL). In a similar manner to the above, the standard and high-substrate 322 
configurations of the PMM-GDP-MP assay were tested for linearity by performing 90 minute time-323 
course reactions using 6.25 nM PMM and 3.13 nM GDP-MP enzymes in the presence of M-6-P (45 324 
µM or 225 µM), G-1,6-BP (6 µM or 30 µM), GTP (150 µM), and inorganic pyrophosphatase  (1 325 
U/mL). In all cases, background control samples were also included that lacked the presence of 326 
enzyme. At the end of the time courses, the biochemical reactions were terminated and absorbance 327 
measurements were taken. Data were acquired from 4 technical replicates (N = 4) for each enzyme 328 
and assay configuration, and were represented as a mean RAU values ± SD following subtraction of 329 
background signal. Linear regression models were fitted to the complete data sets from the standard 330 
and high-substrate configurations of the GDP-MP assay, and for the 30–90 minute and 30–80 minute 331 
time frames for standard and high-substrate configurations of the PMM-GDP-MP assays respectively.  332 
 333 
DMSO tolerance. 334 
DMSO tolerance of the GDP-MP enzyme was investigated by incubating the enzyme (3.13 nM) in the 335 
presence of GTP (30 µM), M-1-P (15 µM), inorganic pyrophosphatase (1 U/mL), and varying 336 
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volumes of DMSO (i.e. 1000 nL, 500 nL, 250 nL, 125 nL, 60 nL, and 30 nL corresponding to 2% v/v, 337 
1% v/v, 0.5% v/v, 0.25% v/v, 0.12% v/v, and 0.06% v/v final assay concentrations respectively) at 338 
room temperature for 60 min. DMSO was added to the assay microplate using a Preddator liquid 339 
dispenser (Redd&Whyte, UK). Background control samples were also included that lacked the 340 
presence of enzyme. At the end of the incubation period, the biochemical reactions were terminated 341 
and absorbance measurements were taken. In a similar manner, DMSO tolerance of the PMM enzyme 342 
was investigated by incubating PMM and GDP-MP enzymes (6.25 nM and 3.13 nM, respectively) in 343 
the presence of GTP (150 µM), M-6-P (45 µM), G-1,6-BP (6 µM), and inorganic pyrophosphatase (1 344 
U/mL). Data were acquired from 4 technical replicates (N = 4) for each enzyme, and were represented 345 
as a mean RAU values + SD following subtraction of background signal. 346 
 347 
Pyrophosphatase counter-screen assay development. 348 
In order to evaluate the activity of the inorganic pyrophosphatase reporter enzyme, a 10-minute time-349 
course reaction using a fixed concentration of the enzyme (1 U/mL) and varying concentrations of 350 
sodium pyrophosphate substrate (20 µM; 10 µM; 5 µM; 2.5 µM; 1.25 µM; and 0 µM) was performed. 351 
Background control samples were also included that lacked the presence of pyrophosphatase enzyme. 352 
At the end of the time-course, the biochemical reactions were terminated and absorbance 353 
measurements were taken. Data were acquired from two technical replicates (N = 2) and were 354 
represented as background subtracted RAU. To confirm the linearity of the assay, the inorganic 355 
pyrophosphatase reporter enzyme (1 U/mL) was incubated at room temperature for 5 min in the 356 
presence of varying concentrations of sodium pyrophosphate substrate (20 µM; 15 µM; 10 µM; 7.5 357 
µM; 5 µM; 3.75 µM; 2.50 µM; 1.88 µM; 1.25 µM; and 0 µM). The colourimetric reaction was 358 
developed and the data were acquired as described above. Data were obtained from 5 technical 359 
replicates (N = 5), and are represented as mean RAU values ± SD following subtraction of 360 
background signal. A linear regression model was fitted to the resulting plot. 361 
 362 
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Single-point diversity screening. 363 
Single-point diversity screening was performed using the standard configuration PMM-GDP-MP 364 
biochemical assay and microplates containing compounds in columns 1–22 from two diverse small-365 
molecule compound sets covering traditional small-molecule chemical space (DDD, 9,257 366 
compounds; molecular weights between 185.2 and 492.2) and more three-dimensional chemical space 367 
(GHCDL, 8,860 compounds; molecular weights between 190.24 and 449.3) at a final concentration of 368 
10 µM (final DMSO concentration = 0.1% v/v), or a small polar set (16,845 primarily fragment-sized 369 
compounds with increased polarity; molecular weights between 88.1 and 476.0) at a final 370 
concentration of 300 µM (final DMSO concentration = 0.3% v/v). Columns 23 and 24 both contained 371 
DMSO (either 0.1% v/v or 0.3% v/v at final assay concentration), and were utilised as ‘maximum 372 
effect’ and ‘minimum effect’ control populations, respectively. For screening purposes, 25 µL of a 373 
solution containing PMM and GDP-MP enzymes (6.25 nM and 3.13 nM, respectively) was added to 374 
columns 1–23, and 25 µL of buffer only was added to column 24. This was followed by the addition 375 
of 25 µL of a mixture containing inorganic pyrophosphatase (1 U/mL) and substrates/co-factors (150 376 
µM GTP, 45 µM M-6-P, and 6 µM G-1,6,-BP). The assay plates were incubated at room temperature 377 
for 90 min. At the end of the incubation period, the biochemical reactions were terminated and 378 
absorbance measurements were taken. Robust Z’ values were calculated for each assay microplate 379 
using the following equation: 380 
 381 
Robust Z’ = 1 – ((3 x (1.483 × (RAU MAD Max)))+(3 x (1.483 × (RAU MAD Min))))/(median RAU 382 
Max - median RAU Min) 383 
 384 
where MAD = median absolute deviation; Max = maximum effect control samples; Min = minimum 385 
effect control samples. 386 
 387 
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RAU values were normalised to % inhibition values relative to the maximum and minimum effect 388 
control populations, and compounds displaying % inhibition values ≥30% were selected as hits. Data 389 
were processed using IDBS ActivityBase 8.1.2.12 and Dotmatics Limited Vortex v2017.08.69598-59-390 
s software. 391 
 392 
 393 
 394 
Concentration-response assays 395 
Concentration-response assessment of hits using the PMM-GDP-MP assays was performed by adding 396 
25 µL of a solution of PMM and GDP-MP enzymes (6.25 nM and 3.13 nM, respectively) to columns 397 
1–11 and 13–23 of microplates containing varying concentrations of compounds (10 final assay 398 
concentrations ranging from 990 µM to 1.92 µM at 1 in 3 dilution increments in the presence of 1% 399 
v/v DMSO). Buffer only (25 µL) was added to columns 12 and 24. Columns 11 and 23 were utilised 400 
as ‘maximum effect’ control populations (1% v/v DMSO with enzyme), and columns 12 and 24 were 401 
‘minimum effect’ control populations (1% v/v DMSO in absence of enzyme). This was followed by 402 
the addition of 25 µL of a mixture containing inorganic pyrophosphatase (1 U/mL) and substrates/co-403 
factors (150 µM GTP, 45 µM M-6-P, and 6 µM G-1,6-BP for the standard configuration assay, and 404 
150 µM GTP, 225 µM M-6-P, and 30 µM G-1,6-BP for the high-substrate configuration assay) to the 405 
entire assay plate. The standard configuration assay plates were incubated at room temperature for 90 406 
min and the high-substrate configuration assay plates were incubated for 80 min. Standard and high-407 
substrate configuration GDP-MP assay compound concentration-response assessments were 408 
performed as above by incubating GDP-MP enzyme (3.13 nM or 0.78 nM) in the presence of GTP 409 
(30 µM or 300 µM), M-1-P (15 µM or 150 µM), and inorganic pyrophosphatase (1 U/mL) for 50 min 410 
at room temperature. Pyrophosphatase counter-screen concentration-response assessments were 411 
performed by pre-incubating compounds with inorganic pyrophosphatase (1 U/mL) for 90 min at 412 
room temperature, followed by addition of inorganic pyrophosphate (10 µM) and a secondary 5 413 
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minute incubation at room temperature. At the end of the incubation periods, the biochemical 414 
reactions were terminated and absorbance measurements were taken. RAU values were normalised to 415 
% inhibition values relative to the maximum and minimum effect control populations. pIC50 values, 416 
defined as –log(IC50 (M)), were calculated by fitting concentration-response data for each independent 417 
replicate separately to a four-parameter logistic model, as shown below, using either the IDBS 418 
ActivityBase 8.1.2.12 or SigmaPlot 12.5 software. Where appropriate, the top curve plateau parameter 419 
was constrained to a value of 100. Compounds requiring a concentration greater than 990 µM to 420 
inhibit biochemical assay activity by at least 50% were deemed to be inactive (i.e. pIC50 <3) 421 
Four-parameter logistic model: 422 
𝑦 = 𝑀𝑖𝑛 +
𝑀𝑎𝑥 − 𝑀𝑖𝑛
1 + (
10−Log𝐼𝐶50
𝑥 )
𝐻𝑖𝑙𝑙𝑠𝑙𝑜𝑝𝑒 
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Figures. 499 
 500 
Figure 1. The GDP-Man biosynthetic pathway in T. cruzi. Glc = glucose; G-6-P = glucose-6-501 
phosphate; G6PI = glucose-6-phosphate isomerase; F-6-P = fructose-6-phosphate; PMI = 502 
phosphomannose isomerase; M-6-P = mannose-6-phosphate; PMM = phosphomannomutase; G-1,6-503 
BP = glucose-1,6-bisphosphate; M-1-P = mannose-1-phosphate; GDP-MP = guanosine diphosphate-504 
mannose pyrophosphorylase; GTP = guanosine triphosphate; GDP-Man = guanosine diphosphate-505 
mannose; GIPLs = glycosylinositol phospholipids; and GPI = glycosylphosphatidylinasitol.  506 
 507 
Figure 2. The biochemical assay platforms. M-6-P = mannose-6-phosphate; PMM = 508 
phosphomannomutase; G-1,6-BP = glucose-1,6-bisphosphate; M-1-P = mannose-1-phosphate; GDP-509 
MP = guanosine diphosphate-mannose pyrophosphorylase; GTP = guanosine triphosphate; GDP-Man 510 
= guanosine diphosphate-mannose; PPiase = pyrophosphatase. 511 
 512 
Figure 3. Michaelis-Menten plots for M-1-P (a) and GTP (b) substrates of the T. cruzi GDP-MP 513 
enzyme obtained using the GDP-MP biochemical assay, and the M-6-P substrate (c) and G-1,6-BP 514 
co-factor (d) of the T. cruzi PMM enzyme obtained using the PMM-GDP-MP biochemical assay. 515 
Data represents mean of three independent replicates (N = 3). Error bars represent ± SD. 516 
 517 
 518 
 519 
 520 
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Table 1. Km parameters for the T. cruzi GDP-MP substrates M-1-P and GTP, and the T. cruzi PMM 521 
substrate M-6-P and the co-factor G-1,6-BP, and the substrate and co-factor concentrations that were 522 
chosen for screening using the standard and high-substrate assay configurations.  523 
Km determinations Screening conditions, µM 
   Standard configuration  High-substrate configuration 
Substrate Km, µM
a
 95% CI, µM GDP-MP PMM-GDP-MP GDP-MP PMM-GDP-MP 
M-1-P 13.3 12.8–13.8 15 - 150 - 
GTP 40.7 31.9–51.6 30 150 300 150 
M-6-P 48.2 44.3–52.4 - 45 - 225 
G-1,6-BP 7.8 6.4–9.5 - 6 - 30 
aData represents mean of three independent replicates (N = 3). 524 
  525 
Figure 4. (a) Single point screen of 18,117 compounds at a concentration of 10 µM from two diversity 526 
compound sets and (b) single point screen of 16,845 compounds at a concentration of 300 µM from a 527 
small polar fragment set using the standard configuration T. cruzi PMM-GDP-MP biochemical assay. 528 
Red circles represent compounds exhibiting ≥30% inhibition. Interfering compounds exhibiting <-529 
100% inhibition were removed. 530 
 531 
Figure 5. Plots showing the linear correlations between pIC50 values of 46 hit compounds obtained for 532 
two independent replicate datasets acquired using (a) the standard configuration T. cruzi PMM-GDP-533 
MP biochemical assay (R2 = 0.98) and (b) the reporter technology interference counter-screen assay 534 
(R2 = 0.93). (c) A plot of the mean pIC50 values (N = 2) for the hit compounds obtained using the 535 
standard configuration T. cruzi PMM-GDP-MP biochemical assay versus the reporter technology 536 
interference counter-screen assay. Red triangles represent 20 compounds that were active against the 537 
former assay (pIC50 ≥3) and inactive against the counter-screen assay (pIC50 <3). 538 
 539 
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Figure 6. A plot showing the linear correlation (R2 = 0.81) between the mean pIC50 values (N = 2) of 540 
the 20 hit compounds obtained using the standard configuration T. cruzi PMM-GDP-MP assay versus 541 
the pIC50 values (N = 1) obtained using the standard configuration T. cruzi GDP-MP assay. 542 
 543 
Table 2. Structures and pIC50 parameters of the four most potent compounds (i.e. compounds 1–4) 544 
acquired using the standard- and high-substrate configuration T. cruzi PMM-GDP-MP and GDP-MP 545 
assays.   546 
 547 
aSC = standard configuration; bHSC = high-substrate configuration; cacquired using library stock 548 
material; dacquired using re-purchased material. Mean pIC50 parameter values are reported where N 549 
≥2. Compounds with a pIC50 <3.0 were deemed inactive in the corresponding biochemical assay.   550 
 o
n
 August 19, 2019 at Brought to you by the University of Dundee Library & Learning Centre
http://aac.asm
.org/
D
ow
nloaded from
 
 o
n
 August 19, 2019 at Brought to you by the University of Dundee Library & Learning Centre
http://aac.asm
.org/
D
ow
nloaded from
 
 o
n
 August 19, 2019 at Brought to you by the University of Dundee Library & Learning Centre
http://aac.asm
.org/
D
ow
nloaded from
 
 o
n
 August 19, 2019 at Brought to you by the University of Dundee Library & Learning Centre
http://aac.asm
.org/
D
ow
nloaded from
 
 o
n
 August 19, 2019 at Brought to you by the University of Dundee Library & Learning Centre
http://aac.asm
.org/
D
ow
nloaded from
 
 o
n
 August 19, 2019 at Brought to you by the University of Dundee Library & Learning Centre
http://aac.asm
.org/
D
ow
nloaded from
 
 o
n
 August 19, 2019 at Brought to you by the University of Dundee Library & Learning Centre
http://aac.asm
.org/
D
ow
nloaded from
 
 o
n
 August 19, 2019 at Brought to you by the University of Dundee Library & Learning Centre
http://aac.asm
.org/
D
ow
nloaded from
 
